Clinical Cancer Research Bridging the Lab and the Clinic in Cancer Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lambooy, L. H. J.
Right arrow Articles by De Abreu, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lambooy, L. H. J.
Right arrow Articles by De Abreu, R. A.
Clinical Cancer Research Vol. 9, 812-819, February 2003
© 2003 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

Real-Time Analysis of Tyrosine Hydroxylase Gene Expression

A Sensitive and Semiquantitative Marker for Minimal Residual Disease Detection of Neuroblastoma1

Lambert H. J. Lambooy, Corrie E. M. Gidding, Lambert P. van den Heuvel, Christina A. Hulsbergen-van de Kaa, Marjolijn Ligtenberg, Jos P. M. Bökkerink and Ronney A. De Abreu2

Departments of Pediatrics [L. H. J. L., C. E. M. G., L. P. v. d. H., J. P. M. B., R. A. D. A.], Pathology [C. A. H. d. K.], and Pathology and Human Genetics [M. L.], University Medical Center Nijmegen, 6500 HB Nijmegen, the Netherlands

Purpose: The purpose of this study was to establish a sensitive and semiquantitativemethod for the detection of minimal residual diseaseof neuroblastoma, the most common solid tumor in childhood.

Experimental Design: Analysis was performed on a molecular level by reverse transcription-PCR using a new, real-time detection method. We measured two genes simultaneously, tyrosine hydroxylase (TH) as the target gene and glyceraldehyde-3-phosphate dehydrogenase as a reference gene, in blood and bone marrow samples at diagnosis and after follow-up from six patients with neuroblastoma, one patient with ganglioneuroma, and one patient with ganglioneuroblastoma.

Results: The sensitivity of the assay was 1:106 peripheral WBCs. Four patients with stage IV neuroblastoma and one patient with stage III neuroblastoma were scored positive. The other stage III patient and the other two patients with ganglioneuroma and ganglioneuroblastoma followed by acute lymphoblastic leukemia, respectively, were scored negative. Control bone marrow aspirates were also negative. The TH assay is more sensitive than immunohistochemical detection, and the results of the TH assay corresponded with the results of MYCN amplification.

Conclusions: The described TH assay is specific, sensitive, and semiquantitative and can be used for the detection of neuroblastoma cell involvement in bone marrow and blood at diagnosis and during therapy. Furthermore, the TH assay is a possible prognostic marker for neuroblastoma.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
A. Schramm, J. Vandesompele, J. H. Schulte, S. Dreesmann, L. Kaderali, B. Brors, R. Eils, F. Speleman, and A. Eggert
Translating Expression Profiling into a Clinically Feasible Test to Predict Neuroblastoma Outcome
Clin. Cancer Res., March 1, 2007; 13(5): 1459 - 1465.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
K. Swerts, B. De Moerloose, C. Dhooge, J. Vandesompele, C. Hoyoux, K. Beiske, Y. Benoit, G. Laureys, and J. Philippe
Potential Application of ELAVL4 Real-Time Quantitative Reverse Transcription-PCR for Detection of Disseminated Neuroblastoma Cells
Clin. Chem., March 1, 2006; 52(3): 438 - 445.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
W. Janni, B. Rack, K. Lindemann, and N. Harbeck
Detection of Micrometastatic Disease in Bone Marrow: Is It Ready for Prime Time?
Oncologist, August 1, 2005; 10(7): 480 - 492.
[Abstract] [Full Text] [PDF]


Home page
J. Mol. Diagn.Home page
M. Fischer, M. Skowron, and F. Berthold
Reliable Transcript Quantification by Real-Time Reverse Transcriptase-Polymerase Chain Reaction in Primary Neuroblastoma Using Normalization to Averaged Expression Levels of the Control Genes HPRT1 and SDHA
J. Mol. Diagn., February 1, 2005; 7(1): 89 - 96.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
S A Burchill
Micrometastases in neuroblastoma: are they clinically important?
J. Clin. Pathol., January 1, 2004; 57(1): 14 - 20.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.